Proteon Therapeutics (NASDAQ:PRTO) received a $2.00 price objective from stock analysts at HC Wainwright in a report issued on Friday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential downside of 18.37% from the stock’s current price.
A number of other brokerages have also weighed in on PRTO. Robert W. Baird set a $3.00 price target on shares of Proteon Therapeutics and gave the stock a “hold” rating in a research note on Wednesday. Zacks Investment Research raised shares of Proteon Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $3.38.
Proteon Therapeutics (NASDAQ PRTO) opened at $2.45 on Friday. The stock has a market cap of $38.00, a PE ratio of -1.16 and a beta of 1.67. Proteon Therapeutics has a one year low of $1.10 and a one year high of $2.85.
Proteon Therapeutics (NASDAQ:PRTO) last issued its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.14. research analysts anticipate that Proteon Therapeutics will post -1.63 EPS for the current year.
An institutional investor recently raised its position in Proteon Therapeutics stock. Renaissance Technologies LLC lifted its stake in Proteon Therapeutics Inc (NASDAQ:PRTO) by 17.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 201,500 shares of the biopharmaceutical company’s stock after acquiring an additional 29,600 shares during the period. Renaissance Technologies LLC owned 1.14% of Proteon Therapeutics worth $383,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 50.56% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/18/proteon-therapeutics-prto-given-a-2-00-price-target-by-hc-wainwright-analysts.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.